Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Moreland

Showing results (121-130 of 130) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 130 results.
The Journal of Pharmacology and Experimental Therapeutics|October 22, 2003
Central mechanisms regulating penile erection in conscious rats: the dopaminergic systems related to the proerectile effect of apomorphineGin C Hsieh, Peter R Hollingsworth, Brenda Martino, et al.
Bioorganic & Medicinal Chemistry Letters|May 12, 2010
Discovery of TRPV1 antagonist ABT-116Brian S Brown, Ryan Keddy, Richard J Perner, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|May 9, 2008
Molecular determinants of species-specific activation or blockade of TRPA1 channelsJun Chen, Xu-Feng Zhang, Michael E Kort, et al.
Journal of Medicinal Chemistry|April 16, 2004
Dopamine D4 ligands and models of receptor activation: 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole and related heteroarylmethylarylpiperazines exhibit a substituent effect responsible for additional efficacy tuningAndrew O Stewart, Marlon D Cowart, Robert B Moreland, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|September 15, 2006
TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonistsM Cui, P Honore, C Zhong, et al.
Journal of Medicinal Chemistry|August 18, 2006
1-aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one oximes as potent dopamine D4 receptor agonists for the treatment of erectile dysfunctionTeodozyj Kolasa, Mark A Matulenko, Ahmed A Hakeem, et al.
Journal of Medicinal Chemistry|July 9, 2004
Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunctionMarlon Cowart, Steven P Latshaw, Pramila Bhatia, et al.
British Journal of Pharmacology|October 4, 2006
Blockade of mGluR1 receptor results in analgesia and disruption of motor and cognitive performances: effects of A-841720, a novel non-competitive mGluR1 receptor antagonistO El-Kouhen, S G Lehto, J B Pan, et al.
Journal of Medicinal Chemistry|December 8, 2006
Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunctionMeena V Patel, Teodozyj Kolasa, Kathleen Mortell, et al.
Physical Review Letters|May 16, 2007
Longitudinal-transverse separations of deep-inelastic structure functions at low Q2 for hydrogen and deuteriumV Tvaskis, M E Christy, J Arrington, et al.
Pageof 13

Showing results (121-130 of 130) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 130 results.
The Journal of Pharmacology and Experimental Therapeutics|October 22, 2003
Central mechanisms regulating penile erection in conscious rats: the dopaminergic systems related to the proerectile effect of apomorphineGin C Hsieh, Peter R Hollingsworth, Brenda Martino, et al.
Bioorganic & Medicinal Chemistry Letters|May 12, 2010
Discovery of TRPV1 antagonist ABT-116Brian S Brown, Ryan Keddy, Richard J Perner, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|May 9, 2008
Molecular determinants of species-specific activation or blockade of TRPA1 channelsJun Chen, Xu-Feng Zhang, Michael E Kort, et al.
Journal of Medicinal Chemistry|April 16, 2004
Dopamine D4 ligands and models of receptor activation: 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole and related heteroarylmethylarylpiperazines exhibit a substituent effect responsible for additional efficacy tuningAndrew O Stewart, Marlon D Cowart, Robert B Moreland, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|September 15, 2006
TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonistsM Cui, P Honore, C Zhong, et al.
Journal of Medicinal Chemistry|August 18, 2006
1-aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one oximes as potent dopamine D4 receptor agonists for the treatment of erectile dysfunctionTeodozyj Kolasa, Mark A Matulenko, Ahmed A Hakeem, et al.
Journal of Medicinal Chemistry|July 9, 2004
Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunctionMarlon Cowart, Steven P Latshaw, Pramila Bhatia, et al.
British Journal of Pharmacology|October 4, 2006
Blockade of mGluR1 receptor results in analgesia and disruption of motor and cognitive performances: effects of A-841720, a novel non-competitive mGluR1 receptor antagonistO El-Kouhen, S G Lehto, J B Pan, et al.
Journal of Medicinal Chemistry|December 8, 2006
Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunctionMeena V Patel, Teodozyj Kolasa, Kathleen Mortell, et al.
Physical Review Letters|May 16, 2007
Longitudinal-transverse separations of deep-inelastic structure functions at low Q2 for hydrogen and deuteriumV Tvaskis, M E Christy, J Arrington, et al.
Pageof 13